Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): Age, dose, and sex effects on immune responses

Archives of Internal Medicine

Volumn 168, Issue 22, 2008, Pages 2405-2414

  Engler, Renata J M ^a   Nelson, Michael R ^a   Klote, Mary M ^a   VanRaden, Mark J ^b   Huang, Chiung Yu ^b   Cox, Nancy J ^c   Klimov, Alexander ^c   Keitel, Wendy A ^d   Nichol, Kristin L ^e   Carr, Warner W ^f   Treanor, John J ^g  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f Allergy & Asthma Associates of Southern California   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP B ANTIGEN; HEMAGGLUTINATION INHIBITING ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FATIGUE; FEMALE; GROUPS BY AGE; HEADACHE; HEMAGGLUTINATION INHIBITION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX; SEX DIFFERENCE; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, VIRAL; FEMALE; HUMANS; INFLUENZA VACCINES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEROLOGIC TESTS; SEX FACTORS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 58149100516     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2008.513     Document Type: Article

References (35)

1. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza vaccines. Vaccine. 2003;21(16):1769-1775.
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179-186.
3. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331(12):778-784.
4. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med. 2001;161(5):749-759.
5. Keech M, Scott AJ, Ryan PJJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond). 1998;48(2):85-90.
6. Smith AP, Thomas M, Brockman P, Kent J, Nicholson KG. Effect of influenza B virus infection on human performance. BMJ. 1993;306(6880):760-761.
7. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med. 1995;333(14):889-893.
8. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2004;53(RR-6):1-40.
9. Treanor J, Keitel W, Belshe R, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002;20(7-8):1099-1105.
10. Gulati U, Kumari K, Wu W, Keitel WA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine. 2005;23(11):1414-1425.
11. Kramer JS, Durham C, Schroeder T, Garrelts JC. Effectiveness of half-dose influenza vaccine in health care workers. Am J Health Syst Pharm. 2006;63(21):2111-2115.
12. Rubertone MV, Brundage JF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health. 2002;92(12):1900-1904.
13. Centers for Disease Control and Prevention. Updated interim influenza vaccination recommendations: 2004-05 influenza season. MMWR Morb Mortal Wkly Rep. 2004;53(50):1183-1184.
14. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 1997;175(1):1-6.
15. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of healthcare workers on mortality of elderly people in long-term care: a randomized controlled trial. Lancet. 2000;355(9198):93-97.
16. Wyatt KN, Ryan GJ, Ssheerin KA. Reduced-dose influenza vaccine. Ann Pharmacother. 2006;40(9):1635-1639.
17. US Influenza Sentinel Provider Surveillance Network. http://www.ccbh.net/ ccbh/export/sites/default/CCBH/pdf/admin/sentinal.provider.pdf. Accessed September 11, 2008.
18. Amadori A, Zamarchi R, De Silvestro G, et al. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med. 1995;1(12):1279-1283.
19. Huygen K, Palfliet K. Strain variation in interferon - production of BCG-sensitized mice challenged with PPD II. Importance of one major autosomal locus and additional sexual influences. Cell Immunol. 1984;85(1):75-81.
20. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2(9):777-780.
21. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wildtype virus. J Clin Microbiol. 1986;24(1):157-160.
22. Dowdle WN, Kendal AP, Noble GR. Influenza viruses. In: Lenette EH, Schmidt NJ, eds. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections. 5th ed. Washington, DC: American Public Health Association; 1979:603-605.
23. Subbarao EK, Kawaoka Y, Ryan-Pourier K, Clements ML, Murphy BR. Comparison of different approaches to measuring influenza A virus-specific hemagglutination inhibition antibodies in the presence of serum inhibitors. J Clin Microbiol. 1992;30(4):996-999.
24. Russell KL, Ryan MA, Hawksworth A, Freed NE, Irvine M, Daum LT; NHRC Respiratory Disease Surveillance Team. Effectiveness of the 2003-2004 influenza vaccine among US military basic trainees: a year of suboptimal match between vaccine and circulating strain. Vaccine. 2005;23(16):1981-1985.
25. Centers for Disease Control and Prevention. Flu activity and surveillance: reports and surveillance methods in the United States. http://www.cdc.gov/flu/weekly/fluactivity.htm. Accessed January 2, 2008.
26. Ruben FL, Jackson GG. A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis. 1972;125(6):656-664.
27. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11(4):411-423.
28. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006;166(10):1121-1127.
29. Jefferson TO, Rivetti D, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007;(2):CD001269.
30. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007;297(14):1577-1582.
31. Kenney RT, Frech SA, Muenz LF, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004;351(22):2295-2301.
32. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med. 2004;351(22):2286-2294.
33. Jackson LA, Austin G, Chen RT, et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine. 2001;19(32):4703-4709.
34. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR. Transcutaneous immunization and immunostimulant strategies. Immunol Allergy Clin North Am. 2003;23(4):787-813.
35. Remarque EJ, de Jong JM, van der Klis RJ, Masurel N, Ligthart GJ. Dose-dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients. Exp Gerontol. 1999;34(1):109-115.